AbCellera Biologics Inc. (ABCL) — Financial statements
Income statement, balance sheet, and cash flow for AbCellera Biologics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 75↑160.6% | 29↓24.2% | 38↓92.2% | 485↑29.4% | 375 | |
| Cost of Revenue | 29 | 0.00 | 0.00↓100.0% | 66↑46.0% | 46 | |
| Gross Profit | 46↑60.6% | 29↓24.2% | 38↓90.9% | 419↑27.1% | 330 | |
| Operating Expenses | ||||||
| R&D Expenses | 187↑11.7% | 167↓4.8% | 176↑62.8% | 108↑73.8% | 62 | |
| General & Administrative Expenses | 0.00↓100.0% | 73↑19.2% | 61↑9.9% | 55↑32.6% | 42 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 13↓9.9% | 14↑25.8% | 11↑63.0% | 7 | |
| SG&A Expenses | 77↓10.4% | 85↑13.7% | 75↑12.6% | 67↑36.9% | 49 | |
| Other Expenses | 0.00↓100.0% | 91↑272.4% | 24↓12.4% | 28↑92.7% | 14 | |
| Operating Expenses | 263↓23.3% | 344↑24.8% | 275↑35.9% | 202↑61.6% | 125 | |
| Total Costs & Expenses | 292↓14.9% | 344↑24.8% | 275↑2.3% | 269↑57.5% | 171 | |
| Operating Results | ||||||
| Operating Income | -217↑31.0% | -315↓32.7% | -237↓209.6% | 217↑5.9% | 204 | |
| Depreciation & Amortization | 29↓70.3% | 97↑214.0% | 31↓6.7% | 33↑91.9% | 17 | |
| EBITDA | -188↑7.8% | -204↓6.2% | -192↓173.9% | 260↑8.8% | 239 | |
| EBIT | -217↑27.9% | -301↓35.0% | -223↓198.2% | 227↑2.3% | 222 | |
| Interest & Other Income | ||||||
| Net Interest Income | 28↓26.4% | 38↓8.9% | 42↑251.1% | 12↑735.0% | -2 | |
| Interest Income | 28↓26.4% | 38↓8.9% | 42↑162.7% | 16↑382.9% | 3 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 4↓22.6% | 5 | |
| Non-Operating Income | 0.00↑100.0% | -14↑3.8% | -14↓34.1% | -11↑39.6% | -17 | |
| Other Income / Expenses | 40↓65.5% | 114↑81.0% | 63↑179.7% | 23↑53.3% | 15 | |
| Income Before Tax | -178↑11.4% | -200↓15.2% | -174↓172.8% | 239↑9.1% | 219 | |
| Income Tax Expense | -31↑16.9% | -38↓35.9% | -28↓134.3% | 81↑22.7% | 66 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -146↑10.1% | -163↓11.2% | -146↓192.4% | 159↑3.3% | 153 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -146↑10.1% | -163↓11.2% | -146↓192.4% | 159↑3.3% | 153 | |
| Bottom-Line Net Income | -146↑10.1% | -163↓11.2% | -146↓192.4% | 159↑3.3% | 153 | |
| EPS (Basic) | -0.49↑10.9% | -0.55↓7.8% | -0.51↓191.1% | 0.56↑0.0% | 0.56 | |
| EPS (Diluted) | -0.49↑10.9% | -0.55↓7.8% | -0.51↓202.0% | 0.50↑4.2% | 0.48 | |
| Weighted Average Shares | 299↑1.5% | 294↑1.8% | 289↑1.4% | 285↑3.4% | 276 | |
| Weighted Average Diluted Shares | 299↑1.5% | 294↑1.8% | 289↓8.2% | 315↓1.1% | 318 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.